Parameter
| Biomarker | phospho-PD-1 | Full name | Phosphorylated programmed cell death protein 1 | Molecular Type | Protein (phosphorylated protein) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Response prediction to treatment, functional abnormal T cell markers |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Tumor-infiltrating lymphocytes (TILs) (monoclonal antibody detection, flow cytometry) | ||
| Pathobiological Mechanisms | The phosphorylation of the intracellular ITSM motif in PD-1 reflects the signaling activity of PD-1, marking activated T cells susceptible to PD-1 inhibition. After PD-1 blockade, its levels decrease. | ||||
| Clinical Availability Status | Research validation phase: Identification of PD-1 signal-activated T cells provides molecular basis for PD-1 immune checkpoint blockade (ICB) therapy response. | ||||
| Notes and Dynamics | The phosphorylation level of PD-1 is prominent in PD-1-positive and TIM-3-positive TILs, while in CD8-positive TILs, the phosphorylation level of PD-1 can serve as an evaluation indicator for ICB efficacy. | ||||